Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

• Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials^(1)
• Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC^(1)
• In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron^(2)

^(https://www.cnbc.com/2026/04/02/novo-nordisk-wegovy-pill-eli-lilly-glp1-stock-nvo-lly-foundayo.html)
https://www.prnewswire.com/news-releases/wegovy-pill-demonstrated-greater-weight-loss-than-orforglipron-and-lower-odds-of-stopping-medication-due-to-side-effects-in-a-new-indirect-comparison-to-be-presented-at-obesity-medicine-association-2026-302732768.html